Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

107.98
-3.7597-3.36%
Volume:2K
Turnover:261.60K
Market Cap:93.94M
PE:- -
High:110.00
Open:110.00
Low:107.04
Close:111.73
52wk High:126.40
52wk Low:55.34
Shares:870.00K
Float Shares:870.00K
Volume Ratio:0.48
T/O Rate:0.28%
Dividend:0.32
Dividend Rate:0.30%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

Stock News
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

Money Quote: a Bad Day for Amgen Stock

Dow Jones
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 09

LIVE Markets-Back to the Post-Summer Grind: Stocks End Red

Reuters
·
Sep 09

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Amgen Stock Poised for Worst Day in More than Two Decades

Dow Jones
·
Sep 09

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?

TradingKey
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09